• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharma Supply Chains: From Fragile to Agile

    Advanced Manufacturing and a Roadmap to the Facility of the Future

    Solving Pharma’s Underlying Rebate Leakage Problem

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Revolutionizing Pharma’s Supply Chain
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems

    "3 Key Trends" with Srinivasan Shanmugam
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Pharmaceutical Continuous Manufacturing: USP Technical Guide

    Mikart Expands Production and Packaging Capabilities

    Flavor Masking for Rx and OTC Drugs

    Prefilled Syringe Production: Filling a Need with Modern Equipment

    Making the Complex, Simple: A Roadmap for Your OSD Journey
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Modern Partnerships with CROs

    Merck KGaA, Quris-AI Expand Collaboration

    BioCity, AstraZeneca Partner on Treatment of Advanced HCC
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Rentschler Biopharma’s ATMP UK Facility Receives MHRA Approval

    Aurisco's Manufacturing Site in China Clears FDA Inspection

    LighthouseAI Secures $2.25M Investment to Grow Supply Chain Products

    Valisure, DoD Conduct Pharmaceutical Quality Risk Assessment Study
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Bachem

    INCOG BioPharma Services

    LOTTE BIOLOGICS

    TaiMed Biologics

    Lannett CDMO
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Bachem

    INCOG BioPharma Services

    LOTTE BIOLOGICS

    TaiMed Biologics

    Lannett CDMO
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Future Trends in the CDMO Space

    And how to navigate them for successful drug development

    Future Trends in the CDMO Space
    Future Trends in the CDMO Space
    Figure 1. A robust and high-yield CHO cell line process successfully scaled up from 3L to 2,000L using single-use equipment
    Future Trends in the CDMO Space
    Figure 2. Switching from stainless-steel to single-use manufacturing leads to a 42% to 100% increase in capacity and a 23% to 42% cost savings per batch.
    Future Trends in the CDMO Space
    Figure 3: KL.a is a function of Vs and P/V. This graph represents the behavior of one specific bioreactor.
    Guillaume Plane, Global Development and Marketing Manager, BioReliance End-to-End Solutions, MilliporeSigma01.25.19
    The requirements of pharmaceutical development and manufacturing are in constant flux. To flourish, contract development and manufacturing organizations (CDMOs) must adapt to ongoing changes and seize the opportunities presented by these changes. At the same time, CDMO customers must understand the trends and select CDMO partners equipped for success.

    Challenges in this arena abound. Increasingly complex biopharma development processes, the growing pressure from drug payers and the advent of biosimilars exert cost pressures. The variable product demand, unknown of whether a product will be a success and intense competition create uncertainty. Emerging markets and the sputtering global economy add to this concern. And unforeseeable, specialized requirements for manufacturing new product classes, such as novel forms of antibody-drug conjugates (ADCs), along with ever-changing regulations and the vagaries of tech transfer make it seem impossible to plan ahead.
    This article will examine these current and forthcoming challenges in drug development and manufacturing—and discuss solutions.

    Payer pressure, biosimilars and emerging markets
    By 2020, according to the IMS Institute for Healthcare Informatics, over $57 billion per year in biologic sales will be off-patent.1 Though dozens of biosimilars are under development and a few are already on the market, the massive patent die-off hasn’t yet prompted the predicted boom of lower-cost biosimilars that is expected to bring relief and savings to patients all over the world. The reality is that to compete with off-patent reference biologics and competing copies, biosimilar drugs must be manufactured more efficiently. However, developing these therapies, even the second time around, is extremely challenging. They are required to have the same structure, activity, clinical efficacy and safety profile as the reference biologics. Expensive development programs—a significant challenge for biosimilars manufacturers under pressure to lower costs and maximize manufacturing flexibility—diminish these projects’ appeal. 

    The overzealous actions of payers and policy makers may compound the problem. According to the IMS, in some countries, certain stakeholders are short-circuiting competition by mandating artificially low prices for biosimilars. But unhampered competition is needed to ensure that manufacturers have the incentive to invest in ongoing development and commercialization of biosimilar products, which is what will eventually lead to real cost savings. A premature focus on lowering cost at the risk of volume is a mistake.

    As time goes on, more and more biosimilars will break through the barriers and come on the market. A huge breakthrough in production costs could trigger a global revolution spurring biosimilar development.2 Geopolitical factors, such as the changing strength of emerging markets or softening of relevant regulatory requirements, as in India,3 can also cause deep shifts in the competitive landscape. Makers of both biologics and biosimilars will undoubtedly be subject to increasing competition. Though the timing and intensity remain uncertain, the ability to keep costs down and the flexibility to tailor yields to match demand will be key.

    Managing biologics production cost
    Maximizing process yield. Time, of course, is money but in upstream development, process yield comes first. Why? Upstream, where the object is to optimize recombinant protein expression to achieve the maximum possible titers in line with time and cost goals, the cost of goods is inversely linked to yield and titer. Choices made here have profound consequences on the success of a biologic candidate. Cell line selection, clone selection, media development and process scale-up considerations all have a direct effect on yield, product quality and how a molecule fares in the face of regulation.

    While the current cost pressures for biological drugs are directed at the end product rather than the cost of development, it’s important to recognize the process needs for maintaining product quality and titers from the beginning. Early analytics development enables developers to modify initial methods to meet process economics for high performance and consistency when manufacturing at scale.

    Process fitting. In addition to developing a robust and high-yield process, such as the CHO cell line producing titers >6g/L as shown in Figure 1 (see the image slider at the top of the page), cost pressures can be managed through process fitting experiments that help reduce a molecule’s manufacturing footprint.

    For example, in one case, a cation exchange chromatography process was converted from a “bind/elute” step, to an “flow-through” step.

    Increased mass loading capacity and decreased conductivity in the second setup signify better, more efficient aggregate removal performance. The second setup also increases productivity through easier column packing, higher flow-through rates, lack of the need for elution, elimination of dilution before later ion exchange steps (no salt) and reduced overall volume to be processed in subsequent virus- and ultra-filtration steps. The second, more efficient column has a smaller footprint and saves raw materials as it requires less resin and buffer to run. In this case, a technology upgrade has improved aggregate removal, increased productivity, reduced overhead and reduced the cost of raw materials.

    Supply and Demand
    When handling trending uncertainties in supply and demand, flexibility is key. Future trends in supply and demand are unknown and unpredictable. Demand for a product depends on how successful it is. Market growth is further subject to the local economy, and competing regional manufacturers may also be a factor. For a CDMO, the key to adapting to this fluctuating state of affairs is flexibility.

    A flexible biologics manufacturing facility features multi-use spaces that can be quickly and easily adapted from one study type or design to the next. Mobile, small-footprint equipment is easy to move and reconfigure into the next manufacturing assembly. Single-use systems lend themselves to flexible manufacturing, from assorted bags up through complete, GMP-scale systems that include processing equipment and reaction vessels. In addition to added flexibility and a small footprint, benefits of these systems include better operator safety, decreased risk of contamination, scalability, reproducibility, lower cost and time saved through efficiencies such as easy setup and cleanup with no cleaning validation requirement.

    Because it requires less preparation time and cleaning, compared with stainless steel, single-use technology, capacity increases by 42% to 100% and achieves a per batch cost savings of 23% to 42% (see Figure 2 in the slider).

    Clearly, these are significant benefits toward trimming timelines and lowering the cost of production. CDMOs must realize, however, that adoption of new technologies always carries some degree of burden. In the case of single-use systems, for example, the facility’s flow and work spaces will be impacted; there will be different workflows. There will no longer be a need for clean-in-place but there will be a new need for bag storage space. Thinking through all the outcomes of any changes before implementation is always wise.

    Tech Transfer
    Tech transfer is important in determining cost and links to a critical need: control. With all the cost pressures previously mentioned—the expense of complex drug development, the unpredictability of market demand or product success, and possible competition from emerging global markets—the ability to scale-up and transfer processes efficiently and effectively is crucial. Wasting time is expensive and can result in missed opportunities. Failure to reproduce any aspect of the original process, from materials to titers, can lead to poor product performance and/or productivity with associated cost consequences.

    Process transfer is performed at multiple steps in the product life cycle, from the development lab to the pilot lab and clinical manufacturing to internal or external manufacturing sites. It should be a tightly organized activity in which the sending and receiving teams agree on clear endpoints and exchange specific knowledge regarding methods, raw materials, equipment, facilities and analytics.

    Because process transfer is truly a keystone of biomanufacturing, transfer skills make a big difference to success. Selecting a CDMO partner with a significant history of tech transfer success helps safeguard the hard development work that has already been done.

    One thing to look for in a potential partner is an effective methodology for obtaining reproducible results in different sizes and models of bioreactors. While bioreactors have similar components—impeller, sparger, reactor, etc.—any change in their size, shape or relationship to other elements will cause variations in reactor temperature gradients, the flow of culture media or the degree of perfusion and mixing. As a result, a cell line will not grow the same way in two different bioreactor models, resulting in altered final batch titers or quality.

    However, mass transfer modeling of the different bioreactors in use can help determine the right equipment settings to achieve uniform titers and reliable end products.
    Consider three bioreactor parameters:

    • Volumetric mass transfer coefficient, KL.a (/hr): a constant function of P/V and Vs ;
    • Power per unit volume, P/V (W/m3): a variable mixing characteristic; and
    • Superficial gas velocity, Vs (m/s): the variable speed of O2 being pumped into the bioreactor.

    Their relationship, for a specific bioreactor, is shown in Figure 3. Different bioreactors exhibit very different relationships among these parameters, resulting in distinctive graphs. The key point, however, is that adjustment of the variables P/V and Vs , in two un-like reactors so that their volumetric mass transfer coefficients are the same, can achieve equivalent cell line growth and titer curves in both bioreactors. A methodology like this helps de-risk tech transfer, maximizing the likelihood of success and minimizing time and cost expenditures.

    Process Intensification & Continuous Manufacturing
    Continuous and intensified processing can increase capacity and speed, lower cost, shrink footprints and mitigate risk. In recent years, biologics developers and manufacturers—with the general support of regulators—have shown great interest in the evolving techniques of process intensification and continuous manufacturing. Still in early adoption phases across the pharmaceutical industry, these techniques are seen to offer great benefits and are starting to be used for both new and established products.

    Continuous processes are far from simple; with so many variables, they must generally be custom-designed for each molecule. And while many companies have adopted elements of intensification and several drug products manufactured with continuous processes have been approved by the FDA, research has shown that few companies consider their processes fully intensified or continuous.4

    Perfusion systems increase productivity over fed-batch systems, accelerating upstream processing, shrinking development timelines and increasing productivity. Gamma-irradiated single-use assemblies help reduce the risk of contamination. The latest cell retention devices, combined with a new understanding of chemical growth media, have run times ranging from 30 to 60 days or more, as opposed to 10 to 12 days for fed-batch operations. Most of these are upstream processes, but there is interest in eventually joining them to downstream processes for fully integrated production that will offer competitive time and cost savings for biopharmaceutical manufacturing.

    The operative word here is will. As a note of caution, even though one might think adoption of the latest, most advanced technologies will propel a development project forward, the opposite can be true. For one thing, the novel technology’s intricacies may not be fully understood. For another, very new technology may not be widely transferrable, limiting later manufacturing options and success. When selecting development and manufacturing processes, it’s crucial to keep the overall product life cycle in mind.

    Navigating Cost Pressures and an Uncertain Market
    Flexibility is the key to navigating today’s cost pressures and uncertain market, while new technologies should be adopted judiciously. Today’s unpredictable production demands make project planning difficult, while cost pressures necessitate that CDMO facilities be highly efficient and filled to capacity. The antidote is flexibility, which allows a manufacturer to transition quickly from one project to another and operate efficiently. One way to attain such flexibility is through single-use systems. Moving equipment from the upstream to the downstream suite, for example, or pricing and margin calculations are far easier with a single-use approach. Ultimately, for a CDMO, flexibility prevents waste and, most importantly, may be what keeps the company thriving.

    While the latest technologies may offer many benefits and efficiencies, innovation must be adopted thoughtfully. If the level of innovation is too high, tech transfer may be difficult or impossible in Phase III. It’s important to strike a balance. For example, continuous processes offer many advantages, but at this time, they would not be reproducible in the majority of manufacturing facilities. The future freedom to transfer a process wherever good business dictates must be carefully considered and preserved throughout development. 

    References
    1. IMS Institute for Healthcare Informatics. Delivering on the potential of biosimilar medicines. Report. March 2016. https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf.
    2. Guillaume Plane. Biosimilars Development – Revolution or Evolution? European Biopharmaceutical Review. Summer 2017. Online. http://www.samedanltd.com/?mod=magazine&id=12&page=article&issid=274&pid=4596&readall.
    3. Bobby George. Changes in Regulatory Requirements for Biosimilar Development In India. Biosimilar Development. November 22, 2016. Online. https://www.biosimilardevelopment.com/doc/changes-in-regulatory-requirements-for-biosimilar-development-in-india-0001.
    4. Rapti Madurawe, Eric Langer, Girish Malhotra, Merilee Whitney, Peter Levison and Dave Sternasty. Continuous Processing. American Pharmaceutical Review. April 20, 2018. Online. https://www.americanpharmaceuticalreview.com/Featured-Articles/349412-Continuous-Processing
    Related Searches
    • biosimilars
    • flexible manufacturing
    • patients
    • analytics
    Suggested For You
    Reed-Lane Reed-Lane
    Vetio Animal Health Vetio Animal Health
    Pelican BioThermal Opens LA Network Station & Service Center Pelican BioThermal Opens LA Network Station & Service Center
    Pricey Buys Pricey Buys
    Akorn Receives FDA Warning Letter Akorn Receives FDA Warning Letter
    Trends in Biologics Manufacturing from Drug Substance to Fill/Finish Trends in Biologics Manufacturing from Drug Substance to Fill/Finish
    Janssen Receives FDA Approval for INVOKANA Janssen Receives FDA Approval for INVOKANA
    Alcami Collaborates with Medicines Development for Global Health Alcami Collaborates with Medicines Development for Global Health
    CPhI CPhI's 15th Annual Pharma Awards
    Possibly Time for a New Paradigm Possibly Time for a New Paradigm
    Reporting CPPs to FDA Reporting CPPs to FDA
    Outsourcing Strategies: Skills and Heritage Outsourcing Strategies: Skills and Heritage
    Improving Pharma R&D Efficiency: The need to transform clinical trials Improving Pharma R&D Efficiency: The need to transform clinical trials
     Symbiosis Secures FDA Approval Symbiosis Secures FDA Approval
    Biosimilar  Market Trends Biosimilar Market Trends

    Related Buyers Guide Companies

    • Serialization | Vials
      Reed-Lane

      Reed-Lane

      Reed-Lane is a privately owned contract packager located in northern New Jersey that has been serving the pharmaceutical market for over 60 years.
      Josh Goolcharan, Director Sales & Marketing 10.25.19

    • Vetio Animal Health

      Vetio Animal Health

      ...
      John Kane, CEO 10.24.19

    • Cold Chain Management | Industry News | Logistics | Packaging & Tracking
      Pelican BioThermal Opens LA Network Station & Service Center

      Pelican BioThermal Opens LA Network Station & Service Center

      New network station brings convenient, flexible shipping options to epicenter of pharmaceutical innovation and logistics
      01.29.19


    • Pricey Buys

      Pricey Buys

      Outbound deals mark M&A activity in 2018
      S. Harachand, Contributing Editor 01.24.19

    • Breaking News | Industry News | Inspections
      Akorn Receives FDA Warning Letter

      Akorn Receives FDA Warning Letter

      Akorn is working collaboratively with the FDA to resolve all issues related to an inspection of its Decatur, IL manufacturing facility
      01.09.19

    Loading, Please Wait..
    Breaking News
    • Univercells Expands into the U.S. With New Offices in Andover, MA
    • Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    • Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    • Sanner Group Opens Second Manufacturing Facility in China
    • Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    View Breaking News >
    CURRENT ISSUE

    September 2023

    • Pharma Supply Chains: From Fragile to Agile
    • Overcoming Stressors in Knowledge Transfer
    • Innovations in Pharma Packaging
    • HPAPI Manufacturing Trends
    • Sustainable Packaging in Pharma: No Longer a Pipe Dream
    • Revolutionizing Pharma’s Supply Chain
    • Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges
    • Solving Pharma’s Underlying Rebate Leakage Problem
    • Advanced Manufacturing and a Roadmap to the Facility of the Future
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    D2C Supplement Brand Launches Blood Sugar Support Supplement, Gluco-Control
    Natrol Launches First Non-Melatonin Sleep Supplement
    Metagenics Releases Consumer Survey on Menopausal Support Supplement
    Coatings World

    Latest Breaking News From Coatings World

    California Sports Surfaces Celebrates 70 Years
    ROSS Offers Cost-Effective, Expertly Reconditioned Equipment
    AkzoNobel Shares Sustainable Architectural Solutions at Conference
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
    SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
    ResMed, Nyxoah Team Up to Grow Sleep Apnea Awareness & Therapy in Germany
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Univercells Expands into the U.S. With New Offices in Andover, MA
    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    YSL Beauty Taps Finn Wolfhard, Lil Yachty & More for Fragrance Campaign
    74% of Makeup Users Open to Affordable ‘Dupes,’ Mintel Says
    Stoelzle Glass Group Names New CEO
    Happi

    Latest Breaking News From Happi

    The Estée Lauder Companies Launches 2023 Breast Cancer Campaign
    BASF Personal Care Introduces New Cosmetic Ingredient
    Breakfast with Oral Care Benefits?
    Ink World

    Latest Breaking News From Ink World

    Siegwerk’s Climate Targets Validated by SBTi
    ROSS Offering Cost-Effective, Expertly Reconditioned Equipment
    Amcor plc Adds Lucrèce Foufopoulos-De Ridder to Board of Directors
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    SABIC and partners launch bio-based IML solution for food packaging
    tesa completes expansion of Michigan manufacturing facility
    Comexi and Asahi to host 'Effortless Platemaking' event
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Greentech Introduces Air Filter with Advanced Odor Elimination
    Ontex Divests Pakistan Operations to ASAIA Holding
    Goodnites Bedwetting Underwear Recognized by Good Housekeeping
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Lazurite Adds Benchmark Medical as a Distributor for its ArthroFree Wireless Camera System
    ChitogenX Granted New U.S., Canadian ORTHO-R Patent
    Centinel Spine prodisc System Surpasses 2,500-Implant Milestone
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Jabil Posts Fourth Quarter, Fiscal Year 2023 Results
    Ink-Borne ‘Chiplets’ Could Lead to Printable Displays, Electronics and More
    SCHOTT Strengthens Glass Substrate Portfolio

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login